Future Tech & AI Wonders · Sam Patel · 17 November 2026

SLS stock jumps after Lilly's $1.5B Calytrix Bio deal

SLS stock jumps after Lilly's $1.5B Calytrix Bio deal

SLS stock jumped as much as 12% after hours Monday as traders compared Sellas Life Sciences' valuation with Eli Lilly's agreement to buy preclinical Calytrix Bio for up to $1.5 billion, nearly matching Sellas's $1.52 billion market value even before Calytrix's lead drug entered human trials.

The after-hours move put blood-cancer deal pricing back in focus for retail and institutional investors tracking Future Tech & AI Wonders biotech valuations.

Key Takeaways

What did Eli Lilly agree to pay for Calytrix Bio?

According to Yahoo Finance reporting, Lilly will pay up to $1.5 billion for Calytrix Bio. The company is a preclinical Massachusetts biotech, and the Business Journals called the purchase Lilly's ninth Massachusetts acquisition since 2024.

Lilly's potential maximum payout was close to Sellas's entire $1.52 billion market value at Monday's close. How much Calytrix shareholders ultimately receive depends on whether the drug reaches clinical and regulatory milestones. The upfront payment was not disclosed.

It was Lilly's second deal this year involving an experimental myelofibrosis treatment. In April, the drugmaker agreed to pay up to $2.3 billion for Ajax Therapeutics, whose lead drug was already in Phase 1 testing. Lilly is reinvesting revenue from weight-loss and diabetes drugs into these oncology bets.

Why did SLS stock jump after the Lilly news?

Traders treated the Calytrix price tag as a valuation clue for Sellas. SLS stock had logged its third straight session of losses before the after-hours rebound of up to 12%.

On Stocktwits, retail sentiment for SLS has been bullish for a week amid a 278% jump in 24-hour message volumes. Some users highlighted how early Lilly was willing to buy a program that has not entered human trials, arguing Sellas may look cheap next to that deal size.

What catalysts are next for Sellas and SLS stock?

Sellas's lead drug, Galinpepimut-S (GPS), is in the Phase 3 Regal trial testing whether the immunotherapy helps acute myeloid leukemia patients live longer after a second remission. Last month the trial reached its 80th death, the threshold for the final survival analysis, and Sellas said last week it expected results in November.

A second candidate, Tambiciclib (SLS009), also has preliminary Phase 2 results due this quarter in newly diagnosed AML, with 40 of a planned 80 patients enrolled. In December, Sellas plans to present findings from a separate study in patients whose leukemia returned or resisted treatment.

Institutional filings showed Prudential added 714,702 shares in the third quarter, while Susquehanna added 587,869 shares. Together the firms held about $41.7 million in Sellas stock on Sept. 30. SLS stock has jumped 98% year-to-date.

← Open in blast feed